<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336282">
  <stage>Registered</stage>
  <submitdate>12/12/2010</submitdate>
  <approvaldate>5/04/2011</approvaldate>
  <actrnumber>ACTRN12611000350921</actrnumber>
  <trial_identification>
    <studytitle>The effects of memantine versus placebo on visual functions of patient with optic neuritis</studytitle>
    <scientifictitle>In patients with optic neuritis, is Memantine as good as or better than placebo for improving visual functions?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>isolated optic neuritis</healthcondition>
    <healthcondition>optic neuritis</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks)</interventions>
    <comparator>Oral administration of placebo (550 miligram of lactose powder) for control group, daily for three weeks (550 mg per day for 3 weeks).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>visual acuity, testing by Early Treatment Diabetic Retinopathy Study (ETDRS) chart in LogMAR (Logarithmic value for Minimum Angle of Resolution)</outcome>
      <timepoint>Baseline, 3 months after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Any change in NFL thickness measured by optical coherence tomography (OCT)</outcome>
      <timepoint>baseline, 3months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Amplitudes of P waves  measured by performing visual evoked  potential</outcome>
      <timepoint>baseline, 3 months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Isolated acute optic neuritis with duration of less than 8 days as patient declares</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>anti-convulsants, barbiturates, neuroleptics, Amantadine hydrochlorothiazids, digoxin and dextrometorphan (interacting with memantine)
Pregnancy or nursing
Renal disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>simple randomisation by using a randomisation table from a statistic book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects, therapist or clinician, assessor, and data analyst were all masked</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of Medical sciences</primarysponsorname>
    <primarysponsoraddress>Tehran university, Enghelab Ave., Enghelab Square, Tehran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran University, Ophthalmology department/ School of medicine/ Medical Sciences</fundingname>
      <fundingaddress>Farabi Eye Hospital, Kargar Ave., Qazvin Square, Tehran 1336616351</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluation of the neuroprotective effect of Memantine in visual function of patients with optic neuritis. Our hypothesis was that Memantine helps for better improvement of visual function in acute optic neuritis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The investigational review board and ethics committees of Tehran University of Medical Sciences</ethicname>
      <ethicaddress>Tehran University eye research center, Farabi eye hospital, Kargar Ave., Qazvin Sq., Tehran 1336616351</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Kargar Ave., Qazvin Square, Tehran 1336616351</address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Kargar Ave., Qazvin Square, Tehran 1336616351</address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sinatums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>